Abstract
The cytochrome P450 belonging to the CYP2B subfamily has long been of great interest because it can be induced by xenobiotics. While a well known diagnostic ligand-receptor theory explains the induction of the CYP1A subfamily, the mechanism by which xenobiotics induce the CYP2B subfamily is not fully understood. Although the constitutive androstane receptor (CAR) undoubtedly plays a crucial role in the induction, many questions regarding the mechanism of CAR activation by xenobiotics have not yet been answered. It is a puzzle that many structurally-unrelated chemicals can increase the expression of the CYP2B subfamily. This may support a mechanism(s) distinct from the signaling induced by ligand-receptor binding. Indeed, phenobarbital, a typical inducer, cannot associate with CAR. Thus, no one is able to answer a fundamental question: what is the initial target of xenobiotics to produce induced expression of CYP2B enzymes? In this review, we survey the research history of CYP2B induction, list the inducers reported so far, and discuss the mechanism of induction including the target site of inducers.
Keywords: CYP2B, phenobarbital, induction, regulation, liver
Current Drug Metabolism
Title: Induction of the Hepatic Cytochrome P450 2B Subfamily by Xenobiotics: Research History, Evolutionary Aspect, Relation to Tumorigenesis, and Mechanism
Volume: 7 Issue: 4
Author(s): Hideyuki Yamada, Yuji Ishii, Midori Yamamoto and Kazuta Oguri
Affiliation:
Keywords: CYP2B, phenobarbital, induction, regulation, liver
Abstract: The cytochrome P450 belonging to the CYP2B subfamily has long been of great interest because it can be induced by xenobiotics. While a well known diagnostic ligand-receptor theory explains the induction of the CYP1A subfamily, the mechanism by which xenobiotics induce the CYP2B subfamily is not fully understood. Although the constitutive androstane receptor (CAR) undoubtedly plays a crucial role in the induction, many questions regarding the mechanism of CAR activation by xenobiotics have not yet been answered. It is a puzzle that many structurally-unrelated chemicals can increase the expression of the CYP2B subfamily. This may support a mechanism(s) distinct from the signaling induced by ligand-receptor binding. Indeed, phenobarbital, a typical inducer, cannot associate with CAR. Thus, no one is able to answer a fundamental question: what is the initial target of xenobiotics to produce induced expression of CYP2B enzymes? In this review, we survey the research history of CYP2B induction, list the inducers reported so far, and discuss the mechanism of induction including the target site of inducers.
Export Options
About this article
Cite this article as:
Yamada Hideyuki, Ishii Yuji, Yamamoto Midori and Oguri Kazuta, Induction of the Hepatic Cytochrome P450 2B Subfamily by Xenobiotics: Research History, Evolutionary Aspect, Relation to Tumorigenesis, and Mechanism, Current Drug Metabolism 2006; 7 (4) . https://dx.doi.org/10.2174/138920006776873508
DOI https://dx.doi.org/10.2174/138920006776873508 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The ErbB Receptors and Their Ligands in PKD, an Overview
Current Signal Transduction Therapy Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy
Current Gene Therapy Role of Radiopharmaceuticals in Development of Inhaled Drugs
Current Pharmaceutical Design Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma
Current Pharmaceutical Design Obesity and Herbal Drug Research: Exploring the Safer Alternative and Lead Molecule
Current Traditional Medicine Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry Aging and Inflammation: Etiological Culprits of Cancer
Current Aging Science Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Sunitinib in the Treatment of Thyroid Cancer
Current Medicinal Chemistry Urea Derivatives as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Hypothalamic mTOR: The Rookie Energy Sensor
Current Molecular Medicine Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets Comprehensive Comparison of Trace Metal Concentrations in Cancerous and Non-Cancerous Human Tissues
Current Medicinal Chemistry Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Current Proteomics